文献速递消化道肿瘤与早癌

肠道罗斯拜瑞菌产生的丁酸盐通过激活细胞毒性CD8+ T细胞增强结直肠癌抗PD-1疗效

Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8+ T cells.
PubMed 文献 · Gut · 2023-07-25

研究比较结直肠癌患者(n=444)与健康对照(n=575)粪便中肠道罗斯拜瑞菌丰度,并在ApcMin/+、AOM诱导及CT26/MC38小鼠模型中验证其作用。结果显示该菌在结直肠癌患者粪便中显著减少,其产生的丁酸盐可抑制肿瘤生长并改善抗PD-1疗效,机制涉及丁酸盐直接结合CD8+ T细胞TLR5受体激活NF-κB信号。

要点

  • 结直肠癌患者粪便中肠道罗斯拜瑞菌丰度较健康对照显著减少。
  • 肠道罗斯拜瑞菌产生的丁酸盐可抑制小鼠结直肠肿瘤生长。
  • 丁酸盐通过结合CD8+ T细胞TLR5受体激活NF-κB信号增强抗PD-1疗效。

核心结论

  • 肠道罗斯拜瑞菌通过产生丁酸盐抑制结直肠肿瘤发生,并可通过诱导功能性CD8+ T细胞改善抗PD-1疗效。
  • 肠道罗斯拜瑞菌是增强抗PD-1治疗结直肠癌疗效的潜在佐剂。

研究设计与样本

  • 评估结直肠癌患者(n=444)与健康对照(n=575)粪便中肠道罗斯拜瑞菌丰度。
  • 在ApcMin/+小鼠及氧化偶氮甲烷(AOM)诱导的结直肠癌小鼠模型中研究肠道罗斯拜瑞菌的作用。
  • 在CT26(微卫星不稳定(MSI)低)或MC38(MSI高)同系小鼠异种移植模型中研究其作用。
  • 采用多色流式细胞术和免疫组织化学染色评估免疫格局变化,并通过代谢组学分析代谢物。

主要发现

  • 与健康对照相比,结直肠癌患者粪便中肠道罗斯拜瑞菌显著减少。
  • 给予肠道罗斯拜瑞菌显著抑制ApcMin/+小鼠的肿瘤形成,并在AOM诱导结直肠癌小鼠中得到证实。
  • 肠道罗斯拜瑞菌恢复肠道屏障功能,表现为肠道通透性改善和紧密连接蛋白表达增强。
  • 丁酸盐被鉴定为肠道罗斯拜瑞菌产生的功能性代谢物。
  • 在MC38或CT26原位小鼠模型中,肠道罗斯拜瑞菌或丁酸盐通过诱导细胞毒性颗粒酶B+、干扰素(IFN)-γ+和肿瘤坏死因子(TNF)-α+ CD8+ T细胞抑制肿瘤生长。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Roseburia intestinalis is a probiotic species that can suppress intestinal inflammation by producing metabolites. We aimed to study the role of R. intestinalis in colorectal tumourigenesis and immunotherapy. DESIGN: R. intestinalis abundance was evaluated in stools of patients with colorectal cancer (CRC) (n=444) and healthy controls (n=575). The effects of R. intestinalis were studied in ApcMin/+ or azoxymethane (AOM)-induced CRC mouse models, and in syngeneic mouse xenograft models of CT26 (microsatellite instability (MSI)-low) or MC38 (MSI-high). The change of immune landscape was evaluated by multicolour flow cytometry and immunohistochemistry staining. Metabolites were profiled by metabolomic profiling. RESULTS: R. intestinalis was significantly depleted in stools of patients with CRC compared with healthy controls. R. intestinalis administration significantly inhibited tumour formation in ApcMin/+ mice, which was confirmed in mice with AOM-induced CRC. R. intestinalis restored gut barrier function as indicated by improved intestinal permeability and enhanced expression of tight junction proteins. Butyrate was identified as the functional metabolite generated by R. intestinalis. R. intestinalis or butyrate suppressed tumour growth by inducing cytotoxic granzyme B+, interferon (IFN)-γ+ and tumour necrosis factor (TNF)-α+ CD8+ T cells in orthotopic mouse models of MC38 or CT26. R. intestinalis or butyrate also significantly improved antiprogrammed cell death protein 1 (anti-PD-1) efficacy in mice bearing MSI-low CT26 tumours. Mechanistically, butyrate directly bound to toll-like receptor 5 (TLR5) receptor on CD8+ T cells to induce its activity through activating nuclear factor kappa B (NF-κB) signalling. CONCLUSION: R. intestinalis protects against colorectal tumourigenesis by producing butyrate, which could also improve anti-PD-1 efficacy by inducing functional CD8+ T cells. R. intestinalis is a potential adjuvant to augment anti-PD-1 efficacy against CRC.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Kang X, Liu C, Ding Y, et al. Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8+ T cells. Gut. 2023. PMID: 37491158. doi:10.1136/gutjnl-2023-330291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。